Both therapies with guselkumab and adalimumab improved social relationships and sexual health in patients with psoriasis compared with placebo at week 12. At week 24, guselkumab was superior to adalimumab regarding the improvement of social relationships and sexual health.
Data on the association of social relationships and sexual health with different psoriasis treatments is scarce. Therefore, an analysis of phase 3, randomised, double-blind VOYAGE 1 and 2 trials (NCT02207231 and NCT02207244) assessed the influence of therapy with guselkumab or adalimumab on social relationships and sexual difficulties in patients with psoriasis . Impairment in these domains was assessed with questions 8 and 9 of the Dermatology Life Quality Index (DLQI) (being question 8 the following: “Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives”, and question 9: “Over the last week, how much has your skin caused any sexual difficulties”). Impaired social relationships and sexual difficulties were defined by a response of “a lot” or “very much”.
At baseline, patients with higher Psoriasis Area and Severity Index (PASI) tended to have also greater difficulties in these domains, which was especially true for women. After treatment with guselkumab and adalimumab, the proportion of participating men and women having difficulties in their social or sexual life declined. Greater improvements were seen in patients with a better PASI response.
At baseline, 31.2% to 34.9% of men and 38.9% to 44.1% of women had difficulties in social relationships. At week 12, a significant improvement could be seen with active treatments compared with placebo in both sexes. Both social and sexual impairments further improved continuously through week 24. At this time, in both sexes, treatment with guselkumab resulted in a significantly lower proportion of patients with impaired social relationships or sexual difficulties versus placebo, but also versus adalimumab. At week 24, only 3.8% of women treated with guselkumab versus 14.1% with adalimumab still had impairment in their social life (P<0.001). The percentage of patients with sexual impairment was similar (2.1% of women treated with guselkumab compared with 11.0% of those treated with adalimumab; P<0.001).
The authors concluded that in both men and women with psoriasis, guselkumab treatment resulted in lower proportions of patients with impaired social relationships or sexual difficulties compared with placebo at week 16 and adalimumab at week 24.
- Armstrong A, et al. Social relationships, sexual difficulty, and the impact of treatment with guselkumab versus adalimumab in men and women with psoriasis: results from VOYAGE 1 and 2. P128, SPIN 2022 Congress, 6-8 July, Paris, France.
Copyright ©2022 Medicom Medical Publishers
« Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas Next Article
IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab »
Table of Contents: SPIN 2022
Letter from the Editor
SPIN 2022 Highlights Podcast
IMIDs in Adults and Children: New Developments
Therapies for atopic dermatitis: still moving forward
Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant
Men on biologics report fewer adverse events than women
Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs
Psoriasis: The Beat Goes On
Systemic treatment for psoriasis: what is on the horizon?
Topical therapy in psoriasis: an important partner in combination therapy
GPP flares: pronounced undertreatment is common
IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas
Psoriasis patients see great benefit in achieving complete skin clearance
The Future Is Bright for Vitiligo
Predilection sites for skin signs of vitiligo disease activity determined
Where Are We Now in Hidradenitis Suppurativa
IHS4 better suited as an outcome measure in HS trials?
New treatments for HS: IL-17 inhibitors next in practice?
New Treatment Options in Alopecia Areata
Alopecia areata: light at the end of the tunnel
Alopecia areata pathogenesis: known genetic background, unknown environmental triggers
Best of the Posters
Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab
Dose tapering in psoriasis is associated with a low relapse rate
IL-17A and IL-17F blockade remarkably effective in psoriasis
Genital psoriasis: high prevalence, often underdiagnosed